Octreotide acetate 中文名称: 奥曲肽

别名: SMS 201-995 acetate; Sandostatin; SMS 201-995; Octreotidum; Octreotida; 79517-01-4; Octreotide acetate 奥曲肽; 醋酸奥曲肽

目录号: V29289 纯度: ≥98%

COA 产品数据产品说明书 SDS

Octreotideacetate (SMS201-995; Sandostatin, SMS201995; Samilstin; Sandostatina;Octreotide-LAR; Longastatin) 是奥曲肽的醋酸盐，是一种八肽和生长抑素类似物，作为 sst2、sst3 和 sst5 生长抑素受体的激动剂。

Octreotide acetate CAS号: 79517-01-4
产品类别: Somatostatin Receptor

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Octreotide acetate:

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Octreotideacetate (SMS201-995; Sandostatin, SMS201995; Samilstin; Sandostatina; Octreotide-LAR; Longastatin) 是奥曲肽的醋酸盐，是一种八肽和生长抑素类似物，作为 sst2、sst3 和 sst5 生长抑素受体的激动剂。已被批准用于治疗激素分泌肿瘤；高胃泌素血症;糖尿病、高血压和小肠瘘。

生物活性&实验参考方法

靶点	SSTR2/3/5
体外研究 (In Vitro)	与盐水组相比，奥曲肽治疗组的肿瘤体积显着降低。与奥曲肽溶液（100 μg/kg，腹腔注射）相比，奥曲肽-PPSG（1.4 mg/kg，腹腔注射）显示出更强的抗肿瘤作用。当将盐水组与原发性 HCC 大鼠进行比较时，奥曲肽治疗显着抑制 SSTR2 和 SSTR5 的表达水平。结果表明，奥曲肽-PPSG 组似乎比奥曲肽-溶液治疗组更能抑制 SSTR2 和 SSTR5 表达[1]。服用醋酸奥曲肽测试剂量后两小时内，胃泌素的血清水平显着降低至基线的三分之一左右。这种效果持续大约六个小时。第 21 天：醋酸奥曲肽（5 mg 肌内注射，每 4 周一次）作为缓释制剂的一部分给药[2]。
体内研究 (In Vivo)	与盐水组相比，奥曲肽治疗组的肿瘤体积显着减小。奥曲肽-PPSG（1.4 mg/kg，腹膜内）显示出比奥曲肽-溶液（100 μg/kg，腹膜内）更强的抗肿瘤作用。与生理盐水组相比，奥曲肽治疗对原发性 HCC 大鼠中 SSTR2 和 SSTR5 的表达水平具有显着的抑制作用。奥曲肽-PPSG 似乎比奥曲肽溶液治疗组更能抑制 SSTR2 和 SSTR5 的表达[1]。测试剂量的醋酸奥曲肽在 2 小时内显着降低血清胃泌素水平至基线的约三分之一，并且效果持续约 6 小时。第 21 天，开始使用醋酸奥曲肽缓释制剂（5 mg 肌内注射，每 4 周一次）进行治疗[2]。
细胞实验	蛋白质印迹分析 [1] 细胞类型：人肝母细胞瘤 HepG2 细胞系测试浓度： 10-8mM 孵育时间：6小时实验结果：磷酸化Akt和GSK3β的蛋白表达水平增加了140.8%。 12.2%和12.2%，GS的mRNA水平也增加。
动物实验	小鼠：将携带肝细胞癌（HCC）异种移植瘤的30只小鼠随机分为三组：（A）奥曲肽溶液组；（B）奥曲肽-PPSG组；（C）对照组。奥曲肽溶液组连续14天，每天腹腔注射100 μg/kg奥曲肽溶液。奥曲肽-PPSG组单次皮下注射约0.2 mL含有1.4 mg/kg奥曲肽-PPSG的溶液。对照组连续14天，每天腹腔注射生理盐水。接种H22肝癌细胞悬液后，于次日开始治疗，持续14天。分别于接种后第7天和第14天使用游标卡尺测量肿瘤大小，以追踪肿瘤生长情况。可使用公式根据肿瘤的长和宽计算肿瘤体积 (V)。大鼠：实验前一周，将两组各 12 只雄性 SD 大鼠置于 25°C 的标准笼中，自由摄食饮水。单次皮下注射相当于 20 mg/kg 的奥曲肽-PPSG 或奥曲肽溶液。剂量计算参考了奥曲肽溶液在人体中的临床剂量。给药后约两小时恢复喂食，给药前禁食 12 小时。使用肝素化 Eppendorf 管按预定时间间隔采集血样。采集血样后立即置于冰上，并在采集后 1 小时内以 3000 g 离心 10 分钟。分析前，收集血浆并保存在 -20°C。
药代性质 (ADME/PK)	吸收、分布和排泄皮下注射后，奥曲肽可完全吸收。口服缓释胶囊后，其峰浓度比皮下注射低33%。口服给药后，Cmax 为 1.67–2.5 小时，而皮下注射仅需 30 分钟。肢端肥大症患者每日两次，每次 20 mg 时，峰浓度为 2.5 mg/nL；而每日两次，每次 40 mg 时，峰浓度为 5.30 ng/mL。无论给药途径如何，AUC均随剂量成正比增加。口服奥曲肽后，约32%经尿液排泄，30-40%经肝脏排泄至粪便。约11%的原药存在于尿液中，2%的原药可从粪便中回收。一项药代动力学研究显示，健康志愿者的分布容积为13.6 L。另一项药代动力学研究显示，健康志愿者静脉给药后，分布容积范围为18.1-30.4 L。奥曲肽的全身清除率为7-10 L/h。一项药代动力学研究显示，奥曲肽的总清除率为 11.4 L/h。代谢/代谢物据报道，奥曲肽主要在肝脏代谢。生物半衰期皮下注射后，血浆半衰期估计为 0.2 小时。皮下和口服给药的平均消除半衰期为 2.3 至 2.7 小时，差异无统计学意义。一项药代动力学研究显示，血浆半衰期为 72 至 113 分钟。
毒性/毒理 (Toxicokinetics/TK)	肝毒性接受奥曲肽治疗的患者中，少数会出现轻度、短暂、无症状的血清转氨酶水平升高；部分患者的转氨酶水平持续升高，且随时间推移而加重，可能需要停药。此外，已有数例由奥曲肽引起的急性、临床表现明显的肝损伤病例报道。肝损伤通常在开始治疗后1至6个月内出现，且剂量越高，肝损伤的发生率可能越高。大多数与奥曲肽治疗相关的肝损伤病例无症状且无黄疸，其特征是血清ALT和AST显著升高，而血清碱性磷酸酶、GGT和胆红素水平正常或接近正常。然而，在某些情况下，尤其是在再次用药后，会出现黄疸。目前尚无与奥曲肽相关的急性肝衰竭或胆管消失综合征病例报道，其损伤的一个特征是停用注射或输注后病情迅速好转。在接受大剂量奥曲肽持续输注治疗的先天性高胰岛素血症新生儿和婴儿中，曾有数例转氨酶显著升高，停药后迅速恢复正常。奥曲肽可抑制胆囊收缩并减少胆汁分泌，长期治疗与高胆固醇胆结石发生率相关。前瞻性研究显示，接受奥曲肽维持治疗的肢端肥大症患者中，25%至65%的患者出现胆结石（经超声检查发现），其中一部分患者发展为症状性胆结石，需要住院治疗和胆囊切除术。即使在胆囊切除术后，胆固醇结石仍可能在胆总管和肝内胆管内形成，引起症状、脓毒症发作，甚至需要进行部分肝切除术。熊去氧胆酸治疗似乎并不能预防奥曲肽治疗期间胆结石的形成，尽管它可能有所帮助。奥曲肽还与急性胰腺炎相关，这可能是由于其对胃肠道激素释放的抑制作用，尽管其他病例可能是由于胆囊结石排出和胰管阻塞所致。可能性评分：C（可能是临床上明显的肝损伤的原因）。妊娠和哺乳期影响 ◉ 哺乳期用药概述尚未研究奥曲肽是否会分泌到母乳中。然而，由于其分子量高达 1019 道尔顿，因此可能很少分泌到母乳中。口服吸收不良，但已安全地通过注射直接给药于婴儿，因此不太可能对母乳喂养的婴儿产生不良影响。至少有 3 名婴儿成功接受母乳喂养，且未报告任何不良反应。在获得更多数据之前，哺乳期妇女应在密切监测婴儿的情况下使用奥曲肽，尤其是在婴儿未满 2 个月的情况下。 ◉ 对母乳喂养婴儿的影响一位母亲在妊娠期和产后接受了奥曲肽治疗肢端肥大症（剂量未说明）。她母乳喂养婴儿 4 个月（喂养时间未说明），婴儿未出现任何明显问题。一位患有肢端肥大症的女性在产后每 6 周接受一次长效奥曲肽（善得定 LAR；剂量未说明）治疗，同时进行母乳喂养。产后6个月，注射频率增加至每4周一次。她母乳喂养婴儿12个月（未说明喂养程度）。孩子5岁时发育正常。 ◉ 对哺乳和母乳的影响一位患有肢端肥大症的孕妇在妊娠12周时开始每月注射10毫克长效奥曲肽。分娩后，她一直母乳喂养至产后6周，之后需要将奥曲肽LAR的剂量增加至每月20毫克。在服用奥曲肽期间，她继续成功地进行母乳喂养。蛋白结合大约65%的剂量在血浆中与脂蛋白和白蛋白结合。
参考文献	[1]. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56. [2]. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12. [3]. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118
其他信息	药效学奥曲肽模拟天然存在的激素——生长抑素。与生长抑素类似，它对生长激素和胰高血糖素具有抑制作用，可用于治疗肢端肥大症患者的组织生长紊乱和胰岛素调节障碍。此外，奥曲肽还能通过减少内脏血流量和多种与腹泻相关的胃肠道激素，缓解胃肠道肿瘤引起的潮红和腹泻。产品标签警告称，奥曲肽可能会降低健康志愿者的胆囊收缩力、胆汁分泌和促甲状腺激素 (TSH) 的释放。此外，已有接受奥曲肽治疗的患者出现维生素 B12 水平降低的报告。服用奥曲肽的患者应密切监测维生素 B12 水平。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C51H70N10O12S2
分子量	1079.29
精确质量	1078.461
元素分析	C, 55.92; H, 6.48; N, 11.86; O, 20.31; S, 5.43
CAS号	79517-01-4
相关CAS号	Octreotide; 83150-76-9; 1607842-55-6 (HCl); 135467-16-2 (Octreotide pamoate)
PubChem CID	448601
外观&性状	White to off-white solid powder
密度	1.4±0.1 g/cm3
沸点	1447.2±65.0 °C at 760 mmHg
熔点	153-156ºC
闪点	829.1±34.3 °C
蒸汽压	0.0±0.3 mmHg at 25°C
折射率	1.673
LogP	0.77
tPSA	382.82
氢键供体(HBD)数目	13
氢键受体(HBA)数目	14
可旋转键数目(RBC)	17
重原子数目	71
分子复杂度/Complexity	1740
定义原子立体中心数目	10
SMILES	C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
InChi Key	DEQANNDTNATYII-OULOTJBUSA-N
InChi Code	InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
化学名	(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
别名	SMS 201-995 acetate; Sandostatin; SMS 201-995; Octreotidum; Octreotida; 79517-01-4; Octreotide acetate
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意：请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮和光照。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	DMSO: ~250 mg/mL (~231.6 mM) H2O: ~25 mg/mL (~23.2 mM)
溶解度 (体内实验)	配方 1 中的溶解度: ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将100 μL 22.5 mg/mL澄清的DMSO储备液加入到400 μL PEG300中，混匀；再向上述溶液中加入50 μL Tween-80，混匀；然后加入450 μL生理盐水定容至1 mL。生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。配方 2 中的溶解度:* ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 22.5 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。 View More* 配方 3 中的溶解度: ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 22.5 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。配方 4 中的溶解度: 100 mg/mL (92.65 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶. 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

DMSO: ~250 mg/mL (~231.6 mM)
H2O: ~25 mg/mL (~23.2 mM)

溶解度 (体内实验)

配方 1 中的溶解度: ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 22.5 mg/mL澄清的DMSO储备液加入到400 μL PEG300中，混匀；再向上述溶液中加入50 μL Tween-80，混匀；然后加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

配方 2 中的溶解度: ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 22.5 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

View More

配方 3 中的溶解度: ≥ 2.25 mg/mL (2.08 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 22.5 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

配方 4 中的溶解度: 100 mg/mL (92.65 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶.

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	0.9265 mL	4.6327 mL	9.2654 mL
	5 mM	0.1853 mL	0.9265 mL	1.8531 mL
	10 mM	0.0927 mL	0.4633 mL	0.9265 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
CTID: NCT05477576
Phase: Phase 3 Status: Recruiting
Date: 2024-11-13

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
CTID: NCT00569127
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-11-13

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer
CTID: NCT04871204
Phase: Phase 2 Status: Completed
Date: 2024-10-31

Treatment of Orthostatic Intolerance
CTID: NCT00262470
Phase: Phase 1/Phase 2 Status: Active, not recruiting
Date: 2024-10-02

Human Models of Selective Insulin Resistance: Pancreatic Clamp
CTID: NCT06558422
Phase: Phase 1 Status: Not yet recruiting
Date: 2024-09-20

View More

Pancreatic Clamp in NAFLD
CTID: NCT05724134
Phase: Phase 1 Status: Recruiting
Date: 2024-09-19

Dexamethasone/Pancreatic Clamp P&F
CTID: NCT06126354
Phase: Phase 1 Status: Withdrawn
Date: 2024-07-10

Outcome of ADPKD With Octreotide LAR
CTID: NCT06193616
Phase: Status: Recruiting
Date: 2024-03-15

Angiotensin 2 for Hepatorenal Syndrome
CTID: NCT04048707
Phase: Phase 2 Status: Withdrawn
Date: 2024-03-06

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
CTID: NCT03179995
Phase: Phase 2 Status: Terminated
Date: 2024-02-14

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
CTID: NCT03624517
Phase: Phase 4 Status: Recruiting
Date: 2024-01-08

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
CTID: NCT03879694
Phase: Phase 1 Status: Recruiting
Date: 2023-12-29

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
CTID: NCT02381249
Phase: N/A Status: Completed
Date: 2023-11-27

Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
CTID: NCT02385617
Phase: N/A Status: Completed
Date: 2023-11-27

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
CTID: NCT03289741
Phase: Phase 4 Status: Completed
Date: 2023-11-07

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
CTID: NCT06085976
Phase: Phase 2 Status: Recruiting
Date: 2023-10-17

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
CTID: NCT00427349
Phase: Phase 2 Status: Completed
Date: 2023-07-05

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
CTID: NCT00003057
Phase: Phase 3 Status: Completed
Date: 2023-06-18

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
CTID: NCT00003283
Phase: Phase 2 Status: Completed
Date: 2023-06-15

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
CTID: NCT02333565
Phase: Phase 2 Status: Completed
Date: 2023-05-25

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
CTID: NCT02384122
Phase: Phase 3 Status: Completed
Date: 2023-05-24

A Feasibility Study of Octreotide Infusion During Liver Transplant.
CTID: NCT04941911
Phase: Phase 2 Status: Active, not recruiting
Date: 2023-05-03

Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock
CTID: NCT03891849
Phase: N/A Status: Withdrawn
Date: 2023-02-09

The Effect of Octreotide on Wound Drainage After Mastectomy
CTID: NCT05682209
Phase: Phase 4 Status: Completed
Date: 2023-01-18

Ghrelin Suppression by Octreotide in Prader-Willi
CTID: NCT01613495
Phase: N/A Status: Unknown status
Date: 2022-12-16

Palliative Management of Inoperable Malignant Bowel Obstruction
CTID: NCT04027348
Phase: Phase 2 Status: Terminated
Date: 2022-11-29

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
CTID: NCT01229943
Phase: Phase 2 Status: Completed
Date: 2022-08-04

Investigation of the Effects of Obesity Surgery on Appetitive Behaviour
CTID: NCT02010385
Phase: N/A Status: Completed
Date: 2022-05-23

Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study
CTID: NCT05199038
Phase: Phase 4 Status: Unknown status
Date: 2022-05-18

Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
CTID: NCT03520569
PhaseEarly Phase 1 Status: Completed
Date: 2022-05-13

Effect of Octreotide on Saliva
CTID: NCT05340192
Phase: Phase 1 Status: Completed
Date: 2022-04-22

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
CTID: NCT02685709
Phase: Phase 3 Status: Completed
Date: 2022-04-22

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
CTID: NCT03158090
Phase: Status: Recruiting
Date: 2022-03-16

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia
CTID: NCT05171751
Phase: Status: Completed
Date: 2021-12-29

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
CTID: NCT02457156
Phase: Phase 3 Status: Unknown status
Date: 2021-12-10

Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)
CTID: NCT04028323
Phase: Phase 4 Status: Unknown status
Date: 2021-08-17

Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
CTID: NCT03734627
Phase: Status: Completed
Date: 2021-08-16

Prevention of Postoperative Pancreatic Fistula by Somatostatin
CTID: NCT03000946
Phase: Phase 3 Status: Completed
Date: 2021-05-03

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
CTID: NCT03252353
Phase: Phase 3 Status: Unknown status
Date: 2020-11-23

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
CTID: NCT02916433
Phase: Phase 2 Status: Completed
Date: 2020-10-08

Octreotide LAR in the Induction of Immunologic Response in NENs Patients
CTID: NCT04129255
Phase: Phase 2 Status: Completed
Date: 2020-09-10

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
CTID: NCT02032784
Phase: Phase 4 Status: Terminated
Date: 2020-07-16

Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
CTID: NCT04353193
Phase: Phase 4 Status: Unknown status
Date: 2020-04-20

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
CTID: NCT00002864
Phase: Phase 3 Status: Completed
Date: 2020-04-01

Stress, Diurnal Cortisol, and Breast Cancer Survival
CTID: NCT00226967
Phase: Status: Completed
Date: 2020-01-27

Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia
CTID: NCT01865760
Phase: N/A Status: Completed
Date: 2019-10-28

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
CTID: NCT04140409
Phase: Phase 4 Status: Terminated
Date: 2019-10-25

Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery
CTID: NCT02437825
Phase: Phase 2 Status: Unknown status
Date: 2019-09-12

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
CTID: NCT02294786
Phase: Phase 2 Status: Terminated
Date: 2019-07-15

Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
CTID: NCT03846180
Phase: Status: Completed
Date: 2019-07-05

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
CTID: NCT03571594
Phase: Phase 1 Status: Terminated
Date: 2019-06-05

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
CTID: NCT01587222
Phase: Phase 2 Status: Withdrawn
Date: 2019-02-15

Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
CTID: NCT03812939
Phase: Status: Unknown status
Date: 2019-01-23

Effects of Glucagon Administration on Energy Expenditure
CTID: NCT02237053
Phase: Phase 1 Status: Completed
Date: 2018-04-26

Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
CTID: NCT00966355
Phase: Phase 4 Status: Completed
Date: 2018-03-19

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
CTID: NCT02217800
Phase: Phase 2 Status: Completed
Date: 2018-02-15

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
CTID: NCT02235987
Phase: Phase 2 Status: Completed
Date: 2018-02-15

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
CTID: NCT01377246
Phase: Phase 3 Status: Completed
Date: 2018-01-10

RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
CTID: NCT03061604
Phase: N/A Status: Completed
Date: 2017-11-14

Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy
CTID: NCT02474914
Phase: N/A Status: Completed
Date: 2017-08-22

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
CTID: NCT01412424
Phase: Phase 3 Status: Completed
Date: 2017-08-17

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
CTID: NCT00600886
Phase: Phase 3 Status: Completed
Date: 2017-07-02

Octreotide in Treating Patients With Cancer-Related Malignant Ascites
CTID: NCT00182754
Phase: Phase 3 Status: Completed
Date: 2017-04-11

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
CTID: NCT00332969
Phase: Phase 2 Status: Completed
Date: 2017-03-31

Octreotide Efficacy and Safety in First-line Acromegalic Patients
CTID: NCT00171886
Phase: Phase 4 Status: Completed
Date: 2017-02-24

Treatment of Orthostatic Hypotension in Autonomic Failure
CTID: NCT00223691
Phase: Phase 1 Status: Completed
Date: 2017-01-18

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
CTID: NCT00002779
Phase: Phase 2 Status: Completed
Date: 2016-12-15

Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
CTID: NCT02977897
Phase: Status: Unknown status
Date: 2016-11-30

Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion
CTID: NCT02920567
Phase: N/A Status: Unknown status
Date: 2016-09-30

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
CTID: NCT02195635
Phase: Phase 1 Status: Completed
Date: 2016-09-07

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
CTID: NCT01204476
Phase: Phase 1 Status: Completed
Date: 2016-07-15

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
CTID: NCT00033605
Phase: Phase 3 Status: Completed
Date: 2016-07-13

Phase II Study With ITF2984 in Acromegalic Patients
CTID: NCT02111044
Phase: Phase 2 Status: Completed
Date: 2016-06-16

Hemodynamic Effects of Terlipressin and High Dose Octreotide
CTID: NCT02119884
Phase: Phase 4 Status: Completed
Date: 2016-06-13

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
CTID: NCT00241020
Phase: Phase 3 Status: Completed
Date: 2016-04-12

Effect of Octreotide on the Colonic Motility in Pediatric Patients
CTID: NCT01917773
Phase: Phase 4 Status: Completed
Date: 2015-12-21

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
CTID: NCT00075868
Phase: Phase 3 Status: Completed
Date: 2015-11-17

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
CTID: NCT00227773
Phase: Phase 2 Status: Withdrawn
Date: 2015-10-08

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
CTID: NCT02427295
Phase: Phase 4 Status: Unknown status
Date: 2015-04-28

Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
CTID: NCT02305069
Phase: N/A Status: Completed
Date: 2014-12-02

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
CTID: NCT01469338
Phase: Phase 2 Status: Terminated
Date: 2014-11-24

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
CTID: NCT00412061
Phase: Phase 3 Status: Completed
Date: 2014-11-21

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
CTID: NCT02217826
Phase: Phase 1 Status: Completed
Date: 2014-08-19

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
CTID: NCT02217839
Phase: Phase 1 Status: Completed
Date: 2014-08-15

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
CTID: NCT00399893
Phase: N/A Status: Terminated
Date: 2014-07-24

Preoperative Octreotide Treatment of Acromegaly
CTID: NCT00521300
Phase: Phase 4 Status: Completed
Date: 2014-06-02

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
CTID: NCT00008073
Phase: Phase 1 Status: Completed
Date: 2013-12-19

Sandostatin for Patients With Androgen Independent Prostate Cancer
CTID: NCT00510224
Phase: Phase 2 Status: Terminated
Date: 2013-12-11

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
CTID: NCT01295060
Phase: Phase 3 Status: Terminated
Date: 2013-09-20

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
CTID: NCT0088
Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial.
CTID: null
Phase: Phase 4 Status: Ongoing
Date: 2020-04-13

A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
CTID: null
Phase: Phase 3 Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2020-02-13

This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diagnosed within 6 months prior to screening, comparing treatment with Lutathera (7.4GBq/200 mCi x 4 administrations every 8± 1 weeks; cumulative dose: 29.6 GBq/800mCi) plus octreotide long-acting (30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment) and high dose octreotide long-acting (60 mg every 4 weeks).
CTID: null
Phase: Phase 3 Status: Trial now transitioned, GB - no longer in EU/EEA, Ongoing
Date: 2019-11-15

A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
CTID: null
Phase: Phase 3 Status: Trial now transitioned, Ongoing, GB - no longer in EU/EEA
Date: 2019-07-12

Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial.
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2019-06-03

A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatin receptor ligands (SRL) treatment
CTID: null
Phase: Phase 3 Status: GB - no longer in EU/EEA, Completed
Date: 2017-10-27

Octreotide LAR in the induction of immunologic response in patient with neuroendocrine tumors: an interventional pharmacological study
CTID: null
Phase: Phase 2 Status: Completed
Date: 2017-07-11

Evaluation of the impact of a Sandostatin injection before axillary node dissection on lymphorrhea in patients operated for breast cancer
CTID: null
Phase: Phase 2 Status: Completed
Date: 2016-05-09

A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPSULES, AND IN PATIENTS TREATED WITH STANDARD OF CARE PARENTERAL SOMATOSTATIN RECEPTOR LIGANDS WHO PREVIOUSLY TOLERATED AND DEMONSTRATED A BIOCHEMICAL CONTROL ON BOTH TREATMENTS
CTID: null
Phase: Phase 3 Status: Prematurely Ended, Completed
Date: 2016-04-18

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2015-12-11

A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal bleeding from angiodysplasias.
CTID: null
Phase: Phase 3 Status: Completed
Date: 2015-09-09

Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01
CTID: null
Phase: Phase 3 Status: Completed
Date: 2015-06-30

A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-08-21

Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study
CTID: null
Phase: Phase 4 Status: Ongoing
Date: 2014-08-05

A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NET) Previously Treated with Sandostatin® LAR®
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-07-02

Sandostatin therapy in sarcoidosis
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2014-06-20

Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-06-05

A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-02-25

Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2014-02-12

AN OPEN, MONOCENTRIC, NOT CONTROLLED CLINICAL TRIAL TO DEVELOP AND EVALUATE THE CLINICAL APPLICATION OF A NEW BETA PROBE FOR RADIOGUIDED SURGERY IN MENINGIOMA TUMOR
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2013-12-13

Imaging with 111In-Octreotide SPECT-CT compared to 68Ga-DOTATATE PET-CT in patients admitted for evaluation of GastroEnteroPancreatic NeuroEndocrine Tumours, GEP-NETs
CTID: null
Phase: Phase 4 Status: Prematurely Ended
Date: 2013-08-22

68Ga-DOTATOC-PET/CT for diagnosis of neuroendocrina tumours
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2012-10-29

A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Cancer
CTID: null
Phase: Phase 2 Status: Completed
Date: 2012-10-09

A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours.
CTID: null
Phase: Phase 3 Status: GB - no longer in EU/EEA, Completed
Date: 2012-04-25

Midrodrine, octeotride and albumin for cirrhotic patients with functional renal impairment
CTID: null
Phase: Phase 4 Status: Completed
Date: 2012-04-03

A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease.
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-10-31

Efficacy and safety of oral Octreolin™ in patients with acromegaly who are currently receiving parenteral somatostatin analogs
CTID: null
Phase: Phase 3 Status: Completed
Date: 2011-08-31

Estudio de prueba de concepto diseñado para evaluar los efectos de Octreolin sobre el gradiente de presión venosa hepática en sujetos con cirrosis e hipertensión portal
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-04-15

A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and moderate to severe renal insufficiency
CTID: null
Phase: Phase 3 Status: Completed
Date: 2011-04-04

A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly
CTID: null
Phase: Phase 3 Status: Completed
Date: 2010-06-10

EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY)
CTID: null
Phase: Phase 3 Status: Prematurely Ended
Date: 2009-11-16

An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment
CTID: null
Phase: Phase 2 Status: Completed
Date: 2009-03-12

PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
CTID: null
Phase: Phase 3 Status: Completed
Date: 2008-10-29

Traitement par Sandostatine LP remplaçant le traitement par Sandostatine SC chez les enfants présentant un hyperinsulinisme congénital résistant au diazoxide.
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2008-09-10

A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotide
CTID: null
Phase: Phase 2 Status: Completed
Date: 2008-02-04

Co-treatment with pegvisomant and a somatostatin analogue (SA) in SA-responsive acromegalic patients: impact on insulin sensitivity, glucose tolerance, and pharmacoeconomics
CTID: null
Phase: Phase 4 Status: Completed
Date: 2008-01-31

A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues
CTID: null
Phase: Phase 3 Status: Completed, Prematurely Ended
Date: 2008-01-14

Receptor radionuclide therapy with [177Lu-
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2008-01-10

Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);
CTID: null
Phase: Phase 4 Status: Completed
Date: 2007-12-20

A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
CTID: null
Phase: Phase 3 Status: Prematurely Ended, Completed
Date: 2007-11-15

OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS
CTID: null
Phase: Phase 3 Status: Completed, Prematurely Ended
Date: 2007-10-29

SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS
CTID: null
Phase: Phase 3 Status: Prematurely Ended
Date: 2007-10-25

An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in acromegalic patients not adequately controlled by conventional regimen
CTID: null
Phase: Phase 3 Status: Completed
Date: 2007-04-20

Phase I study of Somatostatin-Analogues as Second Line Treatment in Adult Patients with Recurrent Medulloblastoma (WHO IV)
CTID: null
Phase: Phase 1, Phase 2 Status: Prematurely Ended
Date: 2007-04-17

Sandostatin® in the treatment of diarrhea in patients with ileal pouch anal anastomosis.
CTID: null
Phase: Phase 4 Status: Completed
Date: 2007-04-10

OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 DAYS FOR 84 DAYS WITH SANDOSTATIN LAR® 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 28 DAYS FOR 84 DAYS TO ACROMEGALIC PATIENTS
CTID: null
Phase: Phase 3 Status: Completed
Date: 2007-02-22

A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® and RAD001 10 mg/d or Sandostatin LAR® and placebo
CTID: null
Phase: Phase 3 Status: Prematurely Ended, Completed
Date: 2007-01-22

phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocrine tumors
CTID: null
PhasePha e.querySelector("font strong").in